Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26521
Title: | Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention? | Authors: | Ariotti, Sara Adamo, Marianna Costa, Francesco Patialiakas, Athanasios Briguori, Carlo Thury, Attila Colangelo, Salvatore Campo, Gianluca Tebaldi, Matteo Ungi, Imre Tondi, Stefano Roffi, Marco Menozzi, Alberto de Cesare, Nicoletta Garbo, Roberto Meliga, Emanuele Testa, Luca Gabriel, Henrique Mesquita Ferlini, Marco VRANCKX, Pascal Valgimigli, Marco |
Issue Date: | 2016 | Source: | JACC-CARDIOVASCULAR INTERVENTIONS, 9(5), p. 426-436 | Abstract: | OBJECTIVES This study sought to investigate the ischemic and bleeding outcomes of patients fulfilling high bleeding risk (HBR) criteria who were randomized to zotarolimus-eluting Endeavor Sprint stent (E-ZES) or bare-metal stent (BMS) implantation followed by an abbreviated dual antiplatelet therapy (DAPT) duration for stable or unstable coronary artery disease. BACKGROUND DES instead of BMS use remains controversial in HBR patients, in whom long-term DAPT poses safety concerns. METHODS The ZEUS (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates) is a multinational, randomized single-blinded trial that randomized among others, in a stratified manner, 828 patients fulfilling pre-defined clinical or biochemical HBR criteria-including advanced age, indication to oral anticoagulants or other pro-hemorrhagic medications, history of bleeding and known anemia-to receive E-ZES or BMS followed by a protocol-mandated 30-day DAPT regimen. The primary endpoint of the study was the 12-month major adverse cardiovascular event rate, consisting of death, myocardial infarction, or target vessel revascularization. RESULTS Compared with patients without, those with 1 or more HBR criteria had worse outcomes, owing to higher ischemic and bleeding risks. Among HBR patients, major adverse cardiovascular events occurred in 22.6% of the E-ZES and 29% of the BMS patients (hazard ratio: 0.75; 95% confidence interval: 0.57 to 0.98; p = 0.033), driven by lower myocardial infarction (3.5% vs. 10.4%; p < 0.001) and target vessel revascularization (5.9% vs. 11.4%; p = 0.005) rates in the E-ZES arm. The composite of definite or probable stent thrombosis was significantly reduced in E-ZES recipients, whereas bleeding events did not differ between stent groups. CONCLUSIONS Among HBR patients with stable or unstable coronary artery disease, E-ZES implantation provides superior efficacy and safety as compared with conventional BMS. (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates [ZEUS]; NCT01385319) (C) 2016 by the American College of Cardiology Foundation. | Keywords: | dual antiplatelet therapy; high bleeding risk; zotarolimus-eluting stent(s) | Document URI: | http://hdl.handle.net/1942/26521 | ISSN: | 1936-8798 | e-ISSN: | 1876-7605 | DOI: | 10.1016/j.jcin.2015.11.015 | ISI #: | 000371921900005 | Rights: | (C) 2016 BY THE AMERICAN COLLEGE OF CARDIOLO GY FOUNDATION | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Bare.pdf Restricted Access | Published version | 972.63 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
69
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
120
checked on Jul 26, 2024
Page view(s)
68
checked on Sep 7, 2022
Download(s)
50
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.